![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Department of Physical Sciences, Chapman University, Orange, California (M.T.G., S.L.); and Department of Pharmacology, School of Medicine, University of California, Irvine, Irvine, California (K.W.F., F.J.E.)
We developed novel methods for analyzing the concentration-response curve of an agonist to estimate the product of observed affinity and intrinsic efficacy, expressed relative to that of a standard agonist. This parameter, termed intrinsic relative activity (RAi), is most applicable for the analysis of responses at G protein-coupled receptors. RAi is equivalent to the potency ratios that agonists would exhibit in a hypothetical, highly sensitive assay in which all agonists behave as full agonists, even those with little intrinsic efficacy. We investigated muscarinic responses at the M2 receptor, including stimulation of phosphoinositide hydrolysis through G
15 in HEK 293T cells, inhibition of cAMP accumulation through Gi in Chinese hamster ovary (CHO) cells, and stimulation of cAMP accumulation through Gs in CHO cells treated with pertussis toxin. The RAi values of carbachol, oxotremorine-M, and the enantiomers of aceclidine were approximately the same in the three assay systems. In contrast, the activity of 4-[[N-[3-chlorophenyl]carbamoy]oxy-2-butynyl]trimethylammonium chloride (McN-A-343) was
10-fold greater at M2 receptors coupled to G
15 in HEK 293T cells compared with M2 receptors coupled to Gi in the same cells or in CHO cells. Our results show that the RAi estimate is a useful measure for quantifying agonist activity across different assay systems and for detecting agonist directed signaling.
Address correspondence to: Dr. Frederick J. Ehlert, Department of Pharmacology, University of California, Irvine, Irvine, CA 92697-4625. E-mail: fjehlert{at}uci.edu
This article has been cited by other articles:
![]() |
C. Valant, P. M. Sexton, and A. Christopoulos Orthosteric/Allosteric Bitopic Ligands: Going Hybrid at GPCRs Mol. Interv., June 1, 2009; 9(3): 125 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Tran, A. Chang, M. Matsui, and F. J. Ehlert Estimation of Relative Microscopic Affinity Constants of Agonists for the Active State of the Receptor in Functional Studies on M2 and M3 Muscarinic Receptors Mol. Pharmacol., February 1, 2009; 75(2): 381 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Figueroa, M. T. Griffin, and F. J. Ehlert Selectivity of Agonists for the Active State of M1 to M4 Muscarinic Receptor Subtypes J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 331 - 342. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Valant, K. J. Gregory, N. E. Hall, P. J. Scammells, M. J. Lew, P. M. Sexton, and A. Christopoulos A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity: MUSCARINIC PARTIAL AGONIST McN-A-343 AS A BITOPIC ORTHOSTERIC/ALLOSTERIC LIGAND J. Biol. Chem., October 24, 2008; 283(43): 29312 - 29321. [Abstract] [Full Text] [PDF] |
||||